CRISPR Therapeutics AG
CRISPR Therapeutics AG, a pioneering biotechnology company headquartered in Switzerland (CH), is at the forefront of gene editing innovation. Founded in 2013, the company focuses on developing transformative therapies using its proprietary CRISPR/Cas9 technology, which allows for precise modifications to DNA. With a strong presence in Europe and North America, CRISPR Therapeutics is dedicated to addressing serious diseases, particularly in the fields of oncology, regenerative medicine, and genetic disorders. Its lead product candidates, including CTX001 for sickle cell disease and beta-thalassemia, exemplify the unique potential of CRISPR technology to provide curative solutions. Recognised for its significant contributions to the industry, CRISPR Therapeutics AG continues to solidify its market position through strategic partnerships and groundbreaking research, making it a key player in the rapidly evolving landscape of gene editing therapies.
DitchCarbon Score
How does CRISPR Therapeutics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CRISPR Therapeutics AG's score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CRISPR Therapeutics AG's reported carbon emissions
CRISPR Therapeutics AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse. In terms of climate commitments, CRISPR Therapeutics AG has not outlined any formal reduction targets or initiatives. There are no details available regarding Science-Based Targets Initiative (SBTi) commitments or other climate pledges. This lack of publicly available data suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the biotechnology industry increasingly prioritises sustainability, CRISPR Therapeutics AG's future climate commitments will be crucial for aligning with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CRISPR Therapeutics AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
